CD30 Antibody [SPM609]

Cancer, Cell Cycle, Immunology, Signal Transduction

Flow Cytometry: 0.5-1 ug/million cells in 0.1ml

Immunofluorescence: 1-2 ug/ml

Immunohistochemistry (FFPE): 0.5-1 ug/ml for 30 min at RT (1)

Prediluted format: incubate for 30 min at RT (2)

Optimal dilution of the CD30 antibody should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 10-20 min followed by cooling at RT for 20 min.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Monoclonal

IgG1, kappa

PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Aliquot and Store at 2-8˚ C. Avoid freez-thaw cycles.

None

943

TNFRSF8

Homo sapiens

Recognizes a single chain glycoprotein of 105/120kDa, identified as CD30/Ki-1. CD30 is synthesized as a 90kDa precursor, which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105/120kDa glycoprotein. In Hodgkin s disease, CD30/Ki-1 antigen is expressed by mononuclear-Hodgkin and multinucleated Reed-Sternberg cells. It is also expressed by the tumor cells of a majority of anaplastic large cell lymphomas as well as by a varying proportion of activated T and B cells. This mAb distinguishes large cell lymphomas derived from activated lymphoid cells from histiocytic malignancies and lymphomas derived from resting and precursor lymphoid cells or from anaplastic carcinomas. About one third of the Ki-1 positive lymphomas lack the leukocyte common antigen (CD45).